| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74ee04ad1428a124f98486b96aef0d8e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0817 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2007-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_182bd098c2526ef806cf33e8a99ad294
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c89774926d75026f1fd0a2cfb7706edd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb8636d2f90e57cad0ae0cb6ad98e247
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6793692fa2a638c875843c0e354fd1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d74c672aef2c4f841f2ed4bac57eb0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b98cbf40bd157f2dbe5bae2bb85de09a |
| publicationDate |
2009-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009286745-A1 |
| titleOfInvention |
Inhibition of alpha-synuclein aggregation |
| abstract |
This invention relates to the inhibition of alpha-synuclein aggregation using peptidyl compounds which are retroenantiomers of the alpha-synuclein sequence, in particular retroenantiomers of sequences in the regions between residues 1 to 60 or residues 61 to 96. Peptidyl compounds of the invention may optionally be coupled to doperminergic targeting moieties and/or blood brain barrier transport moieties and may be useful in the treatment of alpha-synucleinopathies such as Parkinson's disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7915220-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018273498-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11359197-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015139937-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018125813-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11186557-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11447775-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11325966-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012068405-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3521451-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008200397-A1 |
| priorityDate |
2006-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |